Eliem Therapeutics (NASDAQ:ELYM) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.38) by 23.68 percent. This is a 27.5 percent increase over losses of $(0.40) per share from the same period last year.
Mizuho Maintains Buy on Rivian Automotive, Lowers Price Target to $50
Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:RIVN) with a Buy and lowers the price target from $58 to $50.
